Northwest Biotherapeutics makes changes to management team
Linda Powers becomes chief executive
Linda Powers, who has been chairman since May 2007, has become chief executive, while Dr Anthony Maida, a senior executive in the field of cancer immune therapies, is joining the company as chief operating officer on 20 June.
Dr Alton Boynton, the scientific founder of NWBT and chief executive since May 2007, is returning to the position of chief scientific officer.
Les Goldman, a former partner at US law firm Skadden, Arps, specialising in advanced technology commercialisation, has been appointed as senior vice president, business development. Dr Marnix Bosch will continue in his role as chief technology officer.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Pharmaceutical
CellCarta and Leica Biosystems expand companion disgnostic development model partnership
Building on a successful CDx joint development model in China, the pair will aim to bring the end-to-end development framework to global customers to help their customers streamline the path to global CDx commercialisation
Manufacturing
ystral opens ATEX-compliant trial centre in Germany to expand customer process development capacity
The new facility, based in Ballrechten-Dottingen, will be able to handle flammable and explosive media testing across pharma, coatings and food applications, with remote livestream access and in-house particle size and viscosity analysis
Pharmaceutical
CelLBxHealth and AstraZeneca sign Master Services Agreement
The new contract establishes CelLBxHealth as a qualified service provider to AstraZeneca, allowing it to support drug discovery and development through CTC-powered analytics of clinical trial samples with its Parsortix platform